ArticleTherapeutics and clinical risk management2007
Montelukast: its role in the treatment of childhood asthma.
Article in Therapeutics and clinical risk management, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Adverse drug reactions of leukotriene receptor antagonists in children with asthma: a systematic review.BMJ paediatrics open · 2021Pooled it
- Diaphragmatic Mitochondrial Myopathy in a Patient-Derived Mouse Model of Barth Syndrome.Journal of developmental biology · 2026Article
- Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- Effectiveness of adjunctive Xiao-er Kechuanling to terbutaline and montelukast in children with uncontrolled asthma: a prospective observational cohort study.Frontiers in pediatrics · 2025Article
- Myocardial oedema in an 8-year-old Chinese boy with Idiopathic systemic capillary leak syndrome.BMC pediatrics · 2019Article
- Montelukast Improves Symptoms and Lung Function in Asthmatic Women Compared With Men.Frontiers in pharmacology · 2019Article
- Effects of Montelukast on free radical production in whole blood and isolated human polymorphonuclear neutrophils (PMNs) in asthmatic children.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2011Article
- Treatment of congestion in upper respiratory diseases.International journal of general medicine · 2010Article
- Editorial foreword.Therapeutics and clinical risk management · 2007Article
- Awareness and Current Therapeutics of Asthma.Dose-response : a publication of International Hormesis SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cysteinyl leukotrienes, LTC(4), LTD(4), and LTE(4), play an integral role in the pathophysiology of asthma. Acting via the type 1 leukotriene (CysLT(1)) receptor, these proinflammatory mediators have numerous effects in the lungs, including decreased activity of respiratory cilia, increased mucus secretion, increased venopermeability, and promotion of eosinophil migration into airway mucosa. Blocking studies show that Cys-LTs are pivotal mediators in the pathophysiology of asthma. Cys-LTs are key components in the early and late allergic airway response and also contribute to bronchial obstruction after exercise and hyperventilation of cold, dry air in asthmatics. Effects of the cysteinyl leukotrienes are blocked by leukotriene receptor antagonists; these agents inhibit bronchoconstriction in normal subjects provoked with inhaled cysteinyl leukotrienes, as well as in patients with asthma undergoing allergen, exercise, cold air, or aspirin challenge. Montelukast is a potent and selective blocker of the CysLT(1) receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form. Given their efficacy, antiinflammatory activity, oral administration, and safety, leukotriene modifiers will play an important role in the treatment of asthmatic children.
Indexed as
Identifiers
18473012PMC2376066W1540358156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.